Search | Clinical Trials Finder

Conditions: Perinatal Depression
Interventions: Longitudinal Remote Consultation, Collaborative Care; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Malignant Neoplasm
Interventions: FitBit, Gait Assessment Test, MC5-A Scrambler Therapy, Quality-of-Life Assessment, Quantitative Sensory Testing, Questionnaire Administration; Device · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Warts, Verruca (Warts), Verruca Vulgaris
Interventions: 9-valent human papillomavirus vaccine, Sterile Saline; Biological · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Ischemic Stroke
Interventions: Stent Retrievers, Stent Retriever; Device
Lead sponsor: WellStar Health System; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Marietta, Georgia • Roswell, Georgia

Conditions: Testosterone Deficiency
Interventions: Jatenzo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute-graft-versus-host Disease
Interventions: Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: Endometrial Cancer, Recurrent Endometrial Cancer
Interventions: LY3023414; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Tumors, Lymphoma
Interventions: CNF2024; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • New Haven, Connecticut • San Antonio, Texas

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Substance Use Disorders, HIV
Interventions: Population level patient portal based substance involvement screening, Usual Care Substance Use Involvement Screening; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne Vulgaris on the Face
Interventions: DispersinB Acne Cleanser; Device
Lead sponsor: Kane Biotech Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis, Pain
Interventions: Placebo Gel, OLT1177 Gel; Drug
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Birmingham, Alabama • Milford, Connecticut • DeLand, Florida + 10 more

Conditions: Brain Tumor
Interventions: Interstitial Laser Therapy; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions: Labetuzumab Govitecan (LG); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more

Conditions: Opioid-use Disorder, Cocaine Use Disorder, Alcohol Use Disorder
Interventions: NavSTAR; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Post-operative Pain Management
Interventions: Atricure CryoSPHERE MAX Probe; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Waco, Texas

Conditions: Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions: AdV-tk + valacyclovir; Biological
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:; Drug · Radiation
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Obesity
Interventions: Simulated insurance reimbursement; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 19 Years and older
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Head and Neck Cancer
Interventions: Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more

Conditions: Mental Health Issue, Quality of Life
Interventions: Cognitive Behavioral Therapy, Cognitive Behavioral therapy with 2 check in calls; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 110 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Solid Tumor, Adult
Interventions: GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®; Biological · Drug
Lead sponsor: Nouscom SRL; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 9 more

Conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma
Interventions: Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Providence, Rhode Island

Search by objective public record fields.

Remote Supervision for Implementing Collaborative Care for Perinatal Depression

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

Comparison of Solitaire to Embotrap to Treat Large Vessel Occlusion in Acute Ischemic Stroke (SOLTRAP Study)

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

Neurosurgical Use of Interstitial Laser Therapy (ILT)

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Navigation Services to Avoid Rehospitalization (NavSTAR)

Intercostal Cryoanalgesia in Double Lung Transplant Recipients

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Reimbursement Effects on Enrollment in Obesity Treatment

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Telehealth to Improve Quality of Life in Persons Living in Rural Texas

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma